doi: 10.1161/hy1101.092845
(Hypertension. 2001;38:1130.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Enalapril Attenuates Oxidative Stress in Diabetic Rats
From the Massone Institute, Institute of Cardiovascular Research (ININCA) (F.I., I.S., L.F.); Physical Chemistry-PRALIB, School of Pharmacy and Biochemistry, University of Buenos Aires (E.M.V.d.C., C.G.F.); and the Laboratory of Experimental Medicine, Hospital Alemán (J.T.), Buenos Aires, Argentina.
Correspondence to Dr León Ferder, Marcelo T de Alvear 2270, Buenos Aires 1122, Argentina. E-mail leoncho{at}hotmail.com
Abstract—— Oxidative stress is involved in both the pathogenesis and complications of diabetes. ACE inhibitors can slow the progression of cardiac and renal impairments related to diabetes. The effect of enalapril treatment on oxidative stress and tissue injury was studied in hearts, kidneys, and livers from streptozotocin-induced diabetic rats. Twenty-four rats were divided into the following groups: streptozotocin (65 mg/kg, single intraperitoneal dose), streptozotocin+enalapril (20 mg enalapril/L drinking water), and control (intraperitoneal saline). Seven months after streptozotocin injection, organs were studied by light microscopy and collagen III immunolabeling. Tissue lesions and collagen labeling were graded by a semiquantitative score (0 to 4). Total glutathione content, glutathione redox status (reduced/oxidized glutathione), antioxidant enzyme activities, protein-associated sulfhydryls, thiobarbituric acid–reactive substances, and fluorescent chromolipids were determined in tissue homogenates. Glycemia was higher in both the streptozotocin and streptozotocin+enalapril groups relative to the control group. In the streptozotocin group, creatinine clearance and body weight were lower, and systolic blood pressure and urinary albumin excretion were higher than in the streptozotocin+enalapril and control groups. Heart, kidney, and liver lesion/labeling scores were significantly higher in the streptozotocin group compared with the streptozotocin+enalapril and control groups. Kidney and liver total glutathione was lower in the streptozotocin group relative to the control group (P<0.05). Enalapril treatment significantly attenuated the reduction of total glutathione. In the heart, kidney, and liver, both glutathione and proteins were relatively more oxidized in the streptozotocin group relative to the control group (P<0.05). Protein and glutathione oxidation were attenuated in the streptozotocin+enalapril group in the 3 tissues studied (P<0.05). Enalapril treatment attenuated the oxidation of lipids in the heart and kidney (P<0.05). Tissue fibrosis scores were inversely correlated with (1) both total glutathione and reduced/oxidized glutathione in heart, kidney, and liver and (2) glutathione reductase activity in the kidney. These results suggest that in streptozotocin-induced diabetic rats, the protective action of enalapril might be mediated, at least in part, by its effect on tissue oxidant/antioxidant status.
Key Words: diabetes mellitus • oxidative stress • angiotensin II • angiotensin-converting enzyme inhibitors • enalapril • diabetic nephropathy
This article has been cited by other articles:
 |
|
 |
|
  J.-a Kim, Y. Wei, and J. R. Sowers Role of Mitochondrial Dysfunction in Insulin Resistance Circ. Res., February 29, 2008; 102(4): 401 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. V. de Cavanagh, L. Ferder, J. E. Toblli, B. Piotrkowski, I. Stella, C. G. Fraga, and F. Inserra Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H456 - H465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Allard, M. Buleon, E. Cellier, I. Renaud, C. Pecher, F. Praddaude, M. Conti, I. Tack, and J.-P. Girolami ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1083 - F1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A Ronchi, M.-C. Irigoyen, and D. E Casarini Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus Journal of Renin-Angiotensin-Aldosterone System, March 1, 2007; 8(1): 34 - 41. [Abstract] [PDF]
|
|
|
|
|
|
S. Li, X. Li, Y.-L. Li, C.-H. Shao, K. R. Bidasee, and G. J. Rozanski Insulin regulation of glutathione and contractile phenotype in diabetic rat ventricular myocytes Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1619 - H1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ichihara, F. Suzuki, T. Nakagawa, Y. Kaneshiro, T. Takemitsu, M. Sakoda, A.H.M. N. Nabi, A. Nishiyama, T. Sugaya, M. Hayashi, et al. Prorenin Receptor Blockade Inhibits Development of Glomerulosclerosis in Diabetic Angiotensin II Type 1a Receptor-Deficient Mice J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1950 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. V. de Cavanagh, J. E. Toblli, L. Ferder, B. Piotrkowski, I. Stella, and F. Inserra Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2006; 290(6): R1616 - R1625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Asbun and F. J. Villarreal The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy J. Am. Coll. Cardiol., February 21, 2006; 47(4): 693 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Coppey, E. P. Davidson, T. W. Rinehart, J. S. Gellett, C. L. Oltman, D. D. Lund, and M. A. Yorek ACE Inhibitor or Angiotensin II Receptor Antagonist Attenuates Diabetic Neuropathy in Streptozotocin-Induced Diabetic Rats Diabetes, February 1, 2006; 55(2): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rugale, M. Cordaillat, A. Mimran, and B. Jover Prevention and Reversal by Enalapril of Target Organ Damage in Angiotensin II Hypertension Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 154 - 160. [Abstract] [PDF]
|
|
|
|
 |
|
 Y Shimoni, D Hunt, M Chuang, K. Y Chen, G Kargacin, and D. L Severson Modulation of potassium currents by angiotensin and oxidative stress in cardiac cells from the diabetic rat J. Physiol., August 15, 2005; 567(1): 177 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fujiki, H. Shimokawa, K. Morikawa, H. Kubota, M. Hatanaka, M.A. H. Talukder, T. Matoba, A. Takeshita, and K. Sunagawa Endothelium-Derived Hydrogen Peroxide Accounts for the Enhancing Effect of an Angiotensin-Converting Enzyme Inhibitor on Endothelium-Derived Hyperpolarizing Factor-Mediated Responses in Mice Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 766 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, Z. Xu, S. Li, and G. J. Rozanski Redox regulation of Ito remodeling in diabetic rat heart Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1417 - H1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J E Toblli, G Cao, G DeRosa, and P Forcada Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor {beta}1 in obese Zucker rats by perindopril Heart, January 1, 2005; 91(1): 80 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Trauernicht, H. Sun, K. P. Patel, and W. G. Mayhan Enalapril Prevents Impaired Nitric Oxide Synthase-Dependent Dilatation of Cerebral Arterioles in Diabetic Rats Stroke, November 1, 2003; 34(11): 2698 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Griendling and G. A. FitzGerald Oxidative Stress and Cardiovascular Injury: Part II: Animal and Human Studies Circulation, October 28, 2003; 108(17): 2034 - 2040. [Full Text] [PDF]
|
|
|
|
|
|
B. Lassegue and R. E. Clempus Vascular NAD(P)H oxidases: specific features, expression, and regulation Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2003; 285(2): R277 - R297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Gowri, J. H. Yu, A. Shaufl, M. A. Sperling, and R. K. Menon Recruitment of a Repressosome Complex at the Growth Hormone Receptor Promoter and Its Potential Role in Diabetic Nephropathy Mol. Cell. Biol., February 1, 2003; 23(3): 815 - 825. [Abstract] [Full Text]
|
|